Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a randomized first-line phase II trial.


BACKGROUND Bone metastases from renal cell carcinoma (RCC) are a major cause of morbidity. Post hoc analysis has suggested that bone turnover markers can identify patients at risk of skeletal-related events (SREs) among those receiving zoledronic acid. This study sought to evaluate the effect on bone metastases of everolimus alone compared with everolimus… (More)
DOI: 10.1016/j.clgc.2014.07.002



Citations per Year

170 Citations

Semantic Scholar estimates that this publication has 170 citations based on the available data.

See our FAQ for additional information.

  • Presentations referencing similar topics